Combined androgen blockade for the treatment of metastatic cancer of the prostate

By Schellhammer P.F.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 622-628

Elsevier

Access to resources Recommend Favorite

Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy - a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer

By van der Kwast T.H.   Tetu B.   Candas B.   Gomez J.-L.   Cusan L.   Labrie F.  

Urology, Vol. 53, Iss. 3, 1999-03 ,pp. : 523-529

Elsevier

Access to resources Recommend Favorite

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review 2

By Schmitt B.   Wilt T.J.   Schellhammer P.F.   DeMasi V.   Sartor O.   Crawford E.D.   Bennett C.L.  

Urology, Vol. 57, Iss. 4, 2001-04 ,pp. : 727-732

Elsevier

Access to resources Recommend Favorite

Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin

By Schlegel P.N.   Kuzma P.   Frick J.   Farkas A.   Gomahr A.   Spitz I.   Chertin B.   Mack D.   Jungwirth A.   King P.   Nash H.   Bardin C.W.   Moo-Young A.  

Urology, Vol. 58, Iss. 4, 2001-10 ,pp. : 578-582

Elsevier

Access to resources Recommend Favorite

Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?

By Sarosdy M.F.   Schellhammer P.F.   Johnson R.   Carroll K.   Kolvenbag G.J.C.M.  

Urology, Vol. 55, Iss. 3, 2000-03 ,pp. : 391-395

Elsevier

Access to resources Recommend Favorite